Business
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is
About this update from Innocare Pharma Ltd. Class A
[{"type":"image","alt":"InnoCare Pharma","displaySize":"","headline":null,"caption":"InnoCare Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/1885e93031454229063957b3a9d6b6ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_HX0Yb8ZoWwOiU8iDHIydw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1885e93031454229063957b3a9d6b6ec","width":300,"height":116}},"lazy":false},{"type":"text","content":"BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval.","length":574,"tagName":"p"},{"type":"text","content":"Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs.","length":151,"tagName":"p"},{"type":"text","content":"In December 2025, zurletrectinib received approval for the treatment of adult and adolescent patients (aged 12 years and older) with solid tumors harboring NTRK gene fusions in China. In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an objective response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively.","length":571,"tagName":"p"},{"type":"text","content":"In October 2025, the data from the Phase I/II clinical trial of zurletrectinib for the treatment of pediatric and adolescent patients with advanced solid tumors were released at the Congress of International Society of Pediatric Oncology (SIOP) 2025 as an oral presentation. Zurletrectinib demonstrated a well-tolerated safety profile and promising antitumor activity in pediatric/ado...